PIP
ADMA icon

Palisades Investment Partners’s ADMA Biologics ADMA Stock Holding History

Palisades Investment Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-398,647
Closed -$7.26M – 50
2025
Q2 		$7.26M Sell
398,647
-11,799
-3% -$241K 3.17% 10
2025
Q1 		$8.14M Buy
410,446
+9,783
+2% +$169K 4.09% 6
2024
Q4 		$6.87M Buy
400,663
+51,658
+15% +$972K 2.9% 12
2024
Q3 		$6.98M Buy
349,005
+19,984
+6% +$311K 3.04% 12
2024
Q2 		$3.68M Buy
+329,021
New +$2.76M 1.82% 20

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Sachem Head Capital Management
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Palisades Investment Partners's ADMA Position: Q3 2025 in Review

Palisades Investment Partners sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 398,647 shares — an estimated $7.26M sold.

Palisades Investment Partners first reported a position in ADMA in Q2 2024 and held it in 5 quarters. The position peaked at $8.14M in Q1 2025. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Palisades Investment Partners reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
  • Palisades Investment Partners sold 398,647 ADMA Biologics shares in Q3 2025, an estimated $7.26M.
  • Palisades Investment Partners first reported a position in ADMA Biologics in Q2 2024 and held it in 5 quarters.
  • Palisades Investment Partners's ADMA Biologics position peaked at $8.14M in Q1 2025.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Palisades Investment Partners's 13F filing for Q3 2025, filed 30 Oct 2025.